Vitamin d boost may extend life in lymphoma patients, trial hopes

NCT ID NCT01787409

Ongoing Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving vitamin D supplements to people with newly diagnosed lymphoma or chronic lymphocytic leukemia who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 participants are being given vitamin D3 or a placebo. The goal is to see if correcting vitamin D insufficiency helps control the disease better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vitamin D3 (cholecalciferol)
What this could lead to: If it works, this could show that correcting vitamin D levels helps people with certain cancers live longer or delay needing treatment.
What could go wrong: This is an early-stage study without a clear phase, and results may not apply to all cancers. Vitamin D is a supplement, so any benefit is likely modest and not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGGRESSIVE NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma B-cell chronic lymphocytic leukemia diffuse large B-cell lymphoma enteropathy-associated T-cell lymphoma extranodal nasal NK/T cell lymphoma hepatosplenic T-cell lymphoma Lymphoma, Extranodal NK-T-Cell mature T-cell and NK-cell non-Hodgkin lymphoma peripheral T-cell lymphoma, not otherwise specified primary cutaneous anaplastic large cell lymphoma primary mediastinal large B-cell lymphoma subcutaneous panniculitis-like T-cell lymphoma T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGGRESSIVE NON-HODGKIN LYMPHOMA ANAPLASTIC LARGE CELL LYMPHOMA ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA CHRONIC LYMPHOCYTIC LEUKEMIA DIFFUSE LARGE B-CELL LYMPHOMA ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA HEPATOSPLENIC T-CELL LYMPHOMA MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA REFRACTORY ANAPLASTIC LARGE CELL LYMPHOMA SMALL LYMPHOCYTIC LYMPHOMA SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA

Contacts and locations

Locations

Emory University/Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States
University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, 52242, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.